Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.63 |
| ▸ | NR4A2 | P43354 | 7/20 | 0.58 |
| ▸ | ASH1L | Q9NR48 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | ATM | Q13315 | 2/20 | 0.51 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.51 |
| ▸ | KIF11 | P52732 | 1/20 | 0.51 |
| ▸ | JAK2 | O60674 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | PARP1 | P09874 | 1/20 | 0.48 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.47 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.47 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | CASP1 | P29466 | 1/20 | 0.46 |
| ▸ | CASP7 | P55210 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6418495 | 0.89 | NR4A2 (0.72) | NPC1NR4A2ASH1LALDH1A1ATM | |
| SCHEMBL23551106 | 0.89 | NPC1 (0.60) | NPC1NR4A2ASH1LALDH1A1ATM | |
| SCHEMBL3734053 | 0.88 | NR4A2 (0.58) | NPC1NR4A2ASH1LALDH1A1ATM | |
| SCHEMBL4780495 | 0.88 | NPC1 (0.66) | NPC1NR4A2ASH1LCREBBPKIF11 | |
| SCHEMBL30899481 | 0.88 | NPC1 (0.66) | NPC1NR4A2ASH1LCREBBPKIF11 | |
| SCHEMBL2493105 | 0.87 | NPC1 (0.64) | NPC1NR4A2ASH1LALDH1A1CREBBP | |
| SCHEMBL30697204 | 0.87 | NPC1 (0.64) | NPC1NR4A2ASH1LALDH1A1CREBBP | |
| SCHEMBL6332786 | 0.84 | NPC1 (0.61) | NPC1NR4A2ASH1LCREBBPKIF11 | |
| SCHEMBL3243814 | 0.83 | MAPT (0.67) | NPC1NR4A2ASH1LALDH1A1CREBBP | |
| SCHEMBL23551205 | 0.83 | NPC1 (0.60) | NPC1NR4A2ASH1LCREBBPKIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090042875-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND USES THEREOF | CELGENE CORPORATION | 2009-02-12 | — | — | US | disclosed |
| US-7468446-B2 | Substituted heterocyclic compounds and uses thereof | CELGENE CORPORATION (US) | 2008-12-23 | — | — | US | disclosed |
| EP-1794139-A2 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND USES THEREOF | CELGENE CORPORATION (US) | 2007-06-13 | — | — | EP | disclosed |
| WO-2006028963-A2 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND USES THEREOF | CELGENE CORPORATION (US) | 2006-03-16 | — | — | WO | disclosed |
| US-20060052596-A1 | Substituted heterocyclic compounds and uses thereof | CELGENE CORPORATION | 2006-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052596-A1 | Substituted heterocyclic compounds and uses thereof | NQO1, LTC4S, VHL | NPC1 844/4885NR4A2 2159/4885ASH1L 2505/4885 |
| US-20090042875-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND USES THEREOF | NQO1, LTC4S, VHL | NPC1 844/4885NR4A2 2159/4885ASH1L 2505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.